CSL Of Australia Could Face Roadblock To U.S. Approval Of Talecris Buy
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL may have trouble getting the approval of U.S. authorities for its acquisition of Talecris Biotherapeutics. The $3.1 billion deal for the blood products company was announced last August, but at least one analyst noted U.S. administrations have changed since then to give greater attention to regulation. The fear is the Federal Trade Commission will block the merger because it would give CSL too much of the blood products market. (Click here for more